December 7, 2023 02:19 PM EST
Pharma

Mer­ck halts tri­al af­ter Keytru­da-Lyn­parza com­bo flunks PhI­II study in lung can­cer

Katherine Lewin

News Reporter

Mer­ck is halt­ing a Phase III tri­al in non-small cell lung can­cer (NSCLC) af­ter its Keytru­da-Lyn­parza com­bo flunked one of the pri­ma­ry end­points in an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

A service from the Financial Times